ScreenerHero

CGEM Cullinan Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · cullinantherapeutics.com
15.63USD-3.82%Mkt Cap: 1.01B $P/E: —

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.01B USD
Enterprise Value713.30M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-219.88M USD
Revenue/Share—
Last Price15.63 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees109
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.92
PEG—
EV/EBITDA-3.22
EV/Revenue—
P/S—
P/B3.25
EPS (TTM)-3.15
EPS (Forward)-2.75
52W Range
5.68057% of range23.19
52W High23.19 USD
52W Low5.680 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-53.80%
ROA-49.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-175.75M USD
CapEx (TTM)49.00K USD
FCF Margin—
FCF Yield-8.87%
Net Debt-332.47M USD
Net Debt/EBITDA1.50
Balance Sheet
Debt/Equity0.01
Current Ratio8.42
Quick Ratio8.29
Book Value/Sh5.00 USD
Cash/Share5.20 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.45 USD
Upside (mean)+114.0%
Target Range23.00 USD – 42.00 USD
23.00+114.0% to mean42.00
# Analysts11
Ownership
Shares Out.64.35M
Float48.09M
Insiders0.43%
Institutions112.64%
Short Interest
Short Ratio12.3d
Short % Float20.84%
Short % Out.14.96%
Shares Short9.63M
Short (prev mo.)10.59M
Technical
SMA 5019.41 (-19.5%)
SMA 20015.38 (+1.6%)
Beta-0.04
S&P 52W Chg16.45%
Avg Vol (30d)1.14M
Avg Vol (10d)1.44M
Technical Indicators
RSI (14)37.3
MACD-1.2439
MACD Signal-0.9990
MACD Hist.-0.2449
BB Upper23.81 USD
BB Middle18.01 USD
BB Lower12.22 USD
BB Width64.33%
ATR (14)1.232 USD
Vol Ratio (20d)0.59x